^
    Back
    Association details:
    Biomarker:JAK1 S646F
    Cancer:Childhood B Acute Lymphoblastic Leukemia
    Drug:Jakafi (ruxolitinib) (JAK2 inhibitor, JAK1 inhibitor)
    Direction:Sensitive
    Evidence:
    Evidence Level:
    Sensitive: D – Preclinical
    Source:
    ASH 2012
    Title:

    Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia

    Published date:
    10/25/2012
    Excerpt:
    We, therefore, investigated the efficacy of the JAK inhibitor ruxolitinib and the mTOR inhibitor rapamycin in xenograft models of 8 pediatric B-ALL cases with and without CRLF2 and JAK genomic lesions….Xenograft V, which harbors a JAK1 S646F mutation without CRLF2 rearrangement (JAK1m/CRLF2NR), responded to ruxolitinib with lower peripheral and splenic blast counts compared with vehicle...
    DOI:
    https://doi.org/10.1182/blood-2012-03-415448